Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
42 participants
OBSERVATIONAL
2010-03-31
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Normoglycemic
Healthy subjects that do not have diabetes
No interventions assigned to this group
Type II Diabetes (HbA1c <7 or 7%)
Subject that have Type II Diabetes with good glucose control with glycated hemoglobin (HbA1c \<7 or 7%)
No interventions assigned to this group
Type II Diabetes (HbA1c between 7.1-9)
Subjects with Type II Diabetes with moderate glucose control (HbA1c between 7.1-9)
No interventions assigned to this group
Type II Diabetes (HbA1c >9%)
Subjects with Type II Diabetes with poor glucose control (HbA1c \>9%)
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adults ages 40-60 yrs old without Diabetes
Exclusion Criteria
* Pregnant Females
* Therapeutically Immuno-compromised
40 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sashwati Roy
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sashwati Roy
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Roy Sashwati, MS, PhD
Role: PRINCIPAL_INVESTIGATOR
Ohio State University Dept of Surgery
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ohio State University Comprehensive Wound Center
Columbus, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Shurtz-Swirski R, Sela S, Herskovits AT, Shasha SM, Shapiro G, Nasser L, Kristal B. Involvement of peripheral polymorphonuclear leukocytes in oxidative stress and inflammation in type 2 diabetic patients. Diabetes Care. 2001 Jan;24(1):104-10. doi: 10.2337/diacare.24.1.104.
Lin X, Candlish JK, Thai AC. Superoxide production by neutrophils from diabetics and normal subjects in response to glucose and galactose. Exp Mol Pathol. 1993 Jun;58(3):229-36. doi: 10.1006/exmp.1993.1020.
Molenaar DM, Palumbo PJ, Wilson WR, Ritts RE Jr. Leukocyte chemotaxis in diabetic patients and their nondiabetic first-degree relatives. Diabetes. 1976;25(2 SUPPL):880-3.
Hill HR, Sauls HS, Dettloff JL, Quie PG. Impaired leukotactic responsiveness in patients with juvenile diabetes mellitus. Clin Immunol Immunopathol. 1974 Apr;2(3):395-403. doi: 10.1016/0090-1229(74)90057-9. No abstract available.
Related Links
Access external resources that provide additional context or updates about the study.
OSU Center for Regenerative Medicine and Cell Based Therapies
OSU Comprehensive Wound Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009H0270
Identifier Type: -
Identifier Source: org_study_id